Licogliflozin

Licogliflozin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	123456-78-9
PubChem	12345678
DrugBank
ChemSpider	12345678
KEGG

Licogliflozin is a pharmaceutical compound that belongs to the class of sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors). It is primarily investigated for its potential use in the treatment of type 2 diabetes mellitus, a chronic condition characterized by insulin resistance and high blood sugar levels.

Mechanism of Action

Licogliflozin works by inhibiting the SGLT2 protein in the proximal tubules of the kidney. This protein is responsible for the reabsorption of glucose from the urine back into the bloodstream. By blocking SGLT2, licogliflozin reduces glucose reabsorption, leading to increased glucose excretion through urine, thereby lowering blood glucose levels.

Pharmacokinetics

Licogliflozin is administered orally and is absorbed in the gastrointestinal tract. It has a bioavailability of approximately 70%. The drug is metabolized primarily in the liver and excreted through both urine and feces. The half-life of licogliflozin is approximately 12 hours, allowing for once-daily dosing.

Clinical Trials

Licogliflozin has undergone several clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. These studies have shown that licogliflozin effectively lowers blood glucose levels and has a favorable safety profile. Common side effects include urinary tract infections and increased urination.

Potential Benefits

In addition to its glucose-lowering effects, licogliflozin may offer other benefits such as weight loss and a reduction in blood pressure. These effects are attributed to the loss of calories through glucose excretion and the osmotic diuresis caused by the drug.

Adverse Effects

While generally well-tolerated, licogliflozin can cause some adverse effects. The most common are related to its mechanism of action, such as urinary tract infections and genital mycotic infections. Rarely, it may cause ketoacidosis or acute kidney injury.

Regulatory Status

As of the latest update, licogliflozin is still under investigation and has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Also see

• Sodium-glucose co-transporter 2 inhibitors
• Type 2 diabetes mellitus
• Pharmacokinetics
• Clinical trials

• 

  Licogliflozin structure